EVERSANA

What EVERSANA does

EVERSANA is a privately held, US-based provider of integrated commercialization services for the global life sciences industry, founded in 2018 and headquartered in Milwaukee, with approximately 6,000 team members across 20+ locations in North America, Europe, and Asia Pacific. The company serves more than 670 client organizations — ranging from emerging biotech startups to large pharmaceutical manufacturers such as Novartis and Boehringer Ingelheim — by delivering end-to-end commercialization across strategy, market access, patient services, agency/marketing, field deployment, and third-party pharmaceutical distribution. Its differentiated go-to-market is built around commercialization models (EVERSANA COMPLETE, EVERSANA REIGNITE, EVERSANA DIRECT, and EVERSANA ONCOLOGY) that allow clients to outsource launch infrastructure rather than build it in-house.

The technology backbone is the EVERSANA ORCHESTRATE Operating System, an AI-powered platform that unifies data, workflows, content, medical/legal/regulatory review, pharmacovigilance, and omnichannel HCP/patient engagement. Layered on top are the AI Agency Platform (a Google Cloud-based AI-as-a-Service marketing platform), the NAVLIN pricing/access data and revenue management platform, the ACTICS eAccess benefits-verification system with 1,500+ payer connections, a URAC-accredited specialty pharmacy, and a 1M+ sq ft third-party logistics network shipping 320M units annually. Significant acquired capabilities include Intouch Group ($950M, 2021), Healthware Group (2023), Accelera Canada (2021), and most recently Waltz Health (~$6B merger, August 2025), the latter adding AI drug-price marketplaces and direct-to-payer technology with Mark Thierer assuming the CEO role.

Commercially, EVERSANA generates revenue through a mix of professional services engagements, managed services (3PL distribution, specialty pharmacy), and subscription/platform licensing (AI Agency Platform as-a-Service). Engagements are typically structured as multi-year contracts, with pricing varying by therapeutic area complexity, geographic scope, and engagement model. Customer wins span oncology (130+ products, including Shorla Oncology, Candel Therapeutics, Xcovery, Citius Oncology, OS Therapies), rare disease (30+ brands), cell and gene therapy, neurology/CNS (500+ SKUs), and digital health (GENinCode, MedRhythms). Operational performance metrics include 98% on-time delivery, 99.96% order accuracy, 95% retention in channel services, and 95% patient satisfaction in specialty pharmacy, while quantified AI-platform outcomes include 90% NBRx lift via ORCHESTRATE Omnichannel, 50% lower cost and faster execution via the AI Agency Platform, and >30% cost savings plus >10% revenue uplift via EVERSANA REIGNITE.

Name

EVERSANA

Legal name

EVERSANA

Website

https://eversana.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

EVERSANA provides integrated end-to-end commercialization services — strategy, market access, AI-powered marketing, patient services, field deployment, and 3PL distribution — to 670+ life sciences companies globally across oncology, rare disease, cell & gene therapy, and neurology.

Ownership category

akta.pro rank

Product category

Pharmaceutical Commercialization Services

NAICS

Professional, Scientific, and Technical Services (54), Software Publishers (51321), Computer Systems Design Services (541512)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Services-Prepackaged Software (7372), Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Pricing & Contracting Strategy (HLAIAKAA)

akta.pro secondary industries

Specialty Pharmacy & Complex Therapy Management Platforms (HLACAKAG), Hospital & Health-System Pharmaceutical Distributors (HLAIAJAD), Medication Inventory, Procurement & Supply Chain (Pharmacy) (HLACAKAI)

Keywords

• Pharmaceutical commercialization services
• Patient hub services
• Market access solutions
• Specialty pharmacy distribution
• Pharmaceutical field deployment

Headquarters

HQ city

Milwaukee

HQ country

United States

HQ region

North America

Offices11 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Integrated Commercialization Services: EVERSANA provides comprehensive commercialization services to life sciences companies including strategy consulting, market access, patient services, marketing, distribution, and field deployment. Revenue is generated through service fees, typically structured as project-based engagements or ongoing service contracts with pharmaceutical and biotech clients.
2. Third-Party Logistics (3PL) Services: Pharmaceutical distribution and logistics services including warehousing, order fulfillment, cold chain management, and supply chain optimization. Revenue generated through per-unit fulfillment fees and service contracts supporting product distribution.
3. AI-Powered Marketing Agency Services: AI-enabled marketing and content generation services licensed to pharmaceutical companies for brand strategy, omnichannel activation, and commercial execution. Revenue generated through service contracts and platform licensing fees.
4. Patient Services and Hub Operations: Patient access, hub services, specialty pharmacy, adherence programs, and affordability solutions including co-pay and patient assistance programs. Revenue generated through per-patient service fees and program management contracts.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

EVERSANA provides integrated pharmaceutical commercialization services to life sciences companies, spanning strategy, market access, patient services (hub, specialty pharmacy, adherence, affordability, in-home nursing), AI-powered marketing and agency services (ORCHESTRATE, AI Agency Platform), NAVLIN pricing and access data, field deployment (sales, MSLs, nurse educators), and third-party logistics distribution and direct-to-provider e-commerce. The company also offers structured commercialization models (COMPLETE Commercialization for launches, DIRECT for direct-to-patient/payer access, REIGNITE for mature brands, and oncology-specific deployment) that combine the services and platforms into ready-to-deploy commercialization engines.

Product overview

EVERSANA is an integrated commercial services platform for the global life sciences industry, combining data, technology, and human engagement to deliver commercialization services across the product lifecycle. The portfolio is organized around three pillars: (1) Commercialization Models — COMPLETE Commercialization (integrated end-to-end launch model), EVERSANA DIRECT (direct-to-patient/payer model), REIGNITE (mature brand optimization), and ONCOLOGY Commercialization (oncology-specific model); (2) Technology Products — the AI Agency Platform (built on Google Cloud, providing generative AI content and omnichannel marketing), the ORCHESTRATE Operating System (AI-powered unification layer with Omnichannel, MLR, and PV modules), and NAVLIN (AI-driven pricing, access data, and revenue management platform); and (3) Integrated Service Lines covering data and analytics (Commercial Analytics, Integrated Patient Analytics, Commercial Intelligence 360, ACTICS eAccess, RWE & HEOR), patient services (Access & Hub, Specialty Pharmacy, Adherence, Affordability/PAP, In-Home Nursing, Clinical Trials), market access and value, marketing and agency solutions, medical affairs, field deployment, distribution and channel management, and strategy consulting. The platform serves more than 670 life sciences organizations globally across oncology, rare disease, cell and gene therapy, neurology/CNS, and digital medicines.

Differentiator

Problem solved

Functional benefit

Brands

• NAVLIN: AI-driven pricing and access data platform for pharmaceutical market access decisions
• ACTICS eAccess
• EVERSANA ORCHESTRATE
• EVERSANA AI Agency Platform
• Waltz Health

Products and services

• AI Agency Platform Enterprise AI platform for life sciences marketing that delivers brand strategy, AI-generated marketing content, omnichannel activation, and performance optimization for pharmaceutical and biotech brand teams. Built on Google Cloud and licensed via AI-as-a-Service, it claims 50% faster execution, 50% lower cost, and 10% average script lift versus traditional agency models.
• EVERSANA ORCHESTRATE Operating System AI-powered operating system unifying data, strategy, content, workflows, and omnichannel execution across the EVERSANA commercialization ecosystem. Powers Omnichannel, Medical-Legal-Regulatory (MLR) review, Pharmacovigilance, and Literature Monitoring & Aggregate Authoring capabilities to deliver measurable client outcomes including 90% NBRx lift versus control and 17% improvement in prior authorization completions.
• NAVLIN Pricing & Access Platform AI-driven pricing and access data platform that enables natural-language queries across global pricing, policy tracking, and revenue management. Includes NAVLIN Price & Access Data, NAVLIN Research & Insights, NAVLIN Software, and NAVLIN Revenue Management modules serving market access decision-making.
• Global Channel Management & 3PL Distribution Tech-driven third-party logistics and lean supply chain solutions for pharmaceutical product delivery, including validated medical product warehousing, cold chain and controlled substances handling, DSCSA/UDI compliance, returns/recall management, and 95% client retention rate. Operates 1M+ sq ft footprint with 320M units shipped annually and 600 product launches per year.
• Direct-to-Provider e-Commerce Proprietary e-commerce platform enabling pharmaceutical manufacturers to sell directly to healthcare providers, pharmacies, hospitals, clinics, and HCP offices, bypassing traditional wholesale distribution while providing real-time visibility into ordering, tracking, and shipping.
• Specialty Pharmacy Services URAC-accredited specialty pharmacy providing integrated clinical support, specialty medication dispensing, temperature-controlled delivery, and coordinated care for complex therapies. Covers 98% of lives via secured PBM and MM contracts, with 95% patient satisfaction, 94% patient adherence, and 96% benefits verification success rate.
• Access & Hub Patient Services Patient hub services providing real-time eligibility checks, electronic prior authorization, benefits verification (via ACTICS eAccess with 1,500+ payer connections), and streamlined enrollment to accelerate patient access to therapy, including copay assistance and specialty pharmacy coordination.
• Field Deployment Solutions Data-driven field sales, medical science liaison, clinical nurse educator, and national account management deployment services that drive access, affordability, and stakeholder engagement for pharmaceutical manufacturers. Includes Urgent Access Programs for rapid therapy access in critical patient situations.
• Medical Deployment Services Deployment of medical science liaisons (MSLs) and medical teams for high-science therapies, supporting scientific exchange, medical affairs, and brand strategy across the product lifecycle. Includes VP of Medical Deployment leadership overseeing oncology and specialty medical affairs field teams.
• Learning & Performance Services Market access, clinical, and selling skills training and curriculum development for pharmaceutical field teams, blending therapeutic expertise with commercial acumen to enable onboarding, continuous learning, and sales performance improvement.
• Adherence Solutions AI-driven predictive analytics combined with high-touch human support to improve patient adherence through health literacy, telehealth, and personalized interventions, intended to reduce therapy abandonment and improve outcomes.
• Affordability, Co-Pay & Patient Assistance Programs Outcomes-based affordability programs combining real-time patient data with personalized financial support, including co-pay programs and patient assistance programs to ease financial burden and streamline coverage pathways for patients.
• In-Home Nursing & Clinical Support Nationwide in-home clinical care delivered through mobile clinicians for drug administration, patient education, care coordination, and complex therapy management, supporting patients receiving infusions or complex regimens outside clinical settings.
• Clinical Trial Programs (Direct-to-Participant) Direct-to-participant clinical trial dispensing model delivering investigational or approved therapies directly to trial participants, reducing site visits, improving retention, and supporting patient experience in decentralized clinical trials. EVERSANA reports 60%+ reduction in site visits with this model.
• EVERSANA COMPLETE Commercialization Award-winning integrated commercialization model aligning strategy, market access, marketing, and supply to launch products faster with greater confidence, providing an alternative to selling, out-licensing, or launching internally. Awarded PM360 2020 Innovative Strategy Award and reported to reduce overspend by 23% versus traditional model launches.
• EVERSANA DIRECT Combines direct-to-patient access models with direct-to-payer technology to address patient experience, costs, transparency, and care coordination. Achieves 95% prescription fill rates (vs. 50% industry average), 90% adherence/refill rates, and 30-50% lower patient acquisition costs versus other channels.
• EVERSANA REIGNITE AI-enabled commercialization model for mature and in-line brand optimization that uses analytics, digital capabilities, and portfolio optimization to deliver >30% cost savings and >10% additional revenue for established pharmaceutical brands.
• EVERSANA ONCOLOGY Commercialization Fit-for-purpose oncology and hematology commercialization model with deep therapeutic expertise, integrated data access and engagement, and ready-to-deploy infrastructure optimized for smaller patient populations and complex oncology launches. Supports 130+ oncology products and 45+ oncology therapy partnerships.
• Patient, Payer & Provider Marketing Insight-led marketing services for pharmaceutical brand teams across patient, payer, and provider audiences, combining creativity, advanced technology, and global expertise to drive breakthrough brand results.
• EVERSANA ONCOLOGY Commercialization Services Specialized commercialization services for oncology and hematology drug manufacturers, including MSL deployment, oncology-specific field sales, dedicated reimbursement support, and integrated patient access, delivered through EVERSANA ONCOLOGY under URAC Rare Disease Center of Excellence 3.0 certification.

Quantifiable outcome

• 95% prescriptions filled (versus 50% industry average) for EVERSANA DIRECT patients
• +14 more outcomes

Named customers15 records

Segments9 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability10 records

Feature6 records

Partnerships

20 partnerships are on record, tiered core, flagship and minor.

• DocereecoreTechnology or Integration · 7 May 2026Participation in Daily Command launch, an AI-powered healthcare marketing operating system co-built with Doceree. 75 senior industry operators including EVERSANA experts participated in development. Platform enters closed beta June 2026.
• Candel TherapeuticsflagshipStrategic or Co-development Partner · 29 April 2026Product commercialization agreement to support potential U.S. commercial launch of aglatimagene besadenovec for intermediate-to high-risk localized prostate cancer with planned BLA submission Q4 2026. EVERSANA provides integrated commercialization services including data and analytics, medical affairs, market access, and field operations.
• IDEA PharmacoreStrategic or Co-development Partner · 29 April 2026Existing Candel Therapeutics partner for pre-commercial workstreams, collaborating with EVERSANA commercialization services.
• Xcovery HoldingsflagshipStrategic or Co-development Partner · 27 April 2026Partnership to support U.S. commercial launch of ENSACOVE (ensartinib), an FDA-approved next-generation ALK inhibitor for adult patients with ALK-positive locally advanced or metastatic NSCLC. EVERSANA provides comprehensive end-to-end commercialization services including market access and commercial teams.
• PrecigencoreStrategic or Co-development Partner · 5 January 2026Precigen participating in Biotech Showcase event hosted by EVERSANA at J.P. Morgan Healthcare Conference. EVERSANA named for potential U.S. commercialization of PAPZIMEOS.
• Trinity Life SciencesminorStrategic or Co-development Partner · 5 November 2025Trinity Life Sciences acquired EVERSANA's advisory services operation in Asia-Pacific and Middle East, expanding Trinity's global presence and ability to serve life sciences companies in the region with localized data-driven solutions.
• OWP PharmaceuticalscoreStrategic or Co-development Partner · 23 October 2025Selected to support U.S. launch of SUBVENITE (lamotrigine) oral suspension, FDA-approved liquid formulation for epilepsy and bipolar disorders for patients with difficulty swallowing tablets. EVERSANA provides commercialization services for U.S. market entry.
• Citius OncologyflagshipStrategic or Co-development Partner · 16 October 2025Exclusive commercialization agreement to support U.S. commercialization of LYMPHIR for cutaneous T-cell lymphoma with planned Q4 2025 launch. EVERSANA provides integrated market entry and launch readiness services.
• Serve You RxcoreStrategic or Co-development Partner · 14 October 2025Waltz Health (now part of EVERSANA) partnership with Serve You Rx leveraging AI-powered Waltz Connect specialty medication platform. Delivered $917 average savings per prescription, 14% overall cost reduction, 90% biosimilar conversion rate including Stelara conversions.
• Waltz HealthcoreStrategic or Co-development Partner · 26 August 2025EVERSANA merged with Waltz Health in a ~$6 billion transaction to form unified healthcare platform combining EVERSANA's global pharmaceutical commercialization services with Waltz Health's AI-powered drug-price marketplaces and direct-to-payer technology. Mark Thierer, Waltz Health co-founder and CEO, became CEO of combined entity. Creates next-generation commercialization model directly connecting life sciences companies to payers, patients, and pharmacy benefit managers, targeting specialty medications and GLP-1s.
• Google CloudcoreTechnology or Integration · 4 August 2025Technology partnership for development of end-to-end AI-powered life sciences marketing agency built on Google Cloud technology. Enables EVERSANA's AI Agency Platform with enterprise-grade infrastructure, data security, and scalability.
• OS TherapiesflagshipStrategic or Co-development Partner · 10 June 2025Selected to lead U.S. commercialization of OST-HER2 for pediatric osteosarcoma.
• Healthware GroupcoreStrategic or Co-development Partner · 11 October 2023Acquired Healthware Group, a full-service agency and innovation consultancy, to expand European and worldwide capabilities. Healthware directly integrated into EVERSANA INTOUCH, creating full-service global agency network with European expertise in digital health innovation and commercialization consulting.
• Shorla OncologyflagshipStrategic or Co-development Partner · 16 May 2023Ongoing partnership for U.S. commercial launches including nelarabine injection for T-cell leukemia and JYLAMVO oral methotrexate solution. Expanded to include dedicated sales force and market access teams for U.S. commercial footprint.
• ChemoMouthpiececoreStrategic or Co-development Partner · 23 March 2023Partnership to support U.S. launch and commercialization of medical device helping cancer patients manage and treat oral mucositis.
• Intouch GroupcoreStrategic or Co-development Partner · 20 October 2021Acquired Intouch Group, a full-service global agency network serving the pharmaceutical industry, for approximately $950 million. Deal integrated Intouch's creative, media, and data analytics services into EVERSANA's commercialization platform to enhance global pharmaceutical commercialization.
• Accelera CanadacoreStrategic or Co-development Partner · 26 July 2021Acquired Accelera Canada and partner companies (Patient Access Solutions, Podium Strategic Partners, Advocacy Solutions) based in Toronto. Expands global commercialization services with end-to-end Canadian pharmaceutical market support, expertise in market access, patient advocacy, and product launch for 50+ companies.
• GENinCodecoreStrategic or Co-development Partner · 14 June 2021Major U.S. commercialization partnership for digital health solutions bringing cardiovascular disease prevention products to market.
• S3 Connected HealthcoreStrategic or Co-development Partner · 26 May 2021Strategic partnership to advance adoption and commercialization of digital health solutions across life sciences industry.
• MedRhythmscoreStrategic or Co-development Partner · 19 May 2021Partnership to launch and commercialize chronic stroke software-based medical device.

Scale indicators19 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Parexel International: Parexel is a global CRO and biopharmaceutical services firm with growing commercial/patient access capabilities post-Goldberg acquisition. It serves similar pharma clients across the development-to-commercialization continuum, though its scale tilts more toward clinical.
• ICON plc: ICON plc is a global clinical research organization (CRO) that acquired PRA Health Sciences and has expanded into commercial and real-world evidence services. It overlaps with EVERSANA's commercial and data analytics offerings, though ICON's core remains clinical development.
• IQVIA: IQVIA is the largest life sciences services and data platform globally, offering clinical, commercial, technology, and real-world evidence solutions. EVERSANA competes most directly with IQVIA's Contract Sales & Medical Solutions and commercialization services, and both target the same pharma/biotech client base for end-to-end commercialization support.
• McKesson Corporation: McKesson is the largest pharmaceutical distributor in North America and a major provider of specialty pharmacy, patient services, and biopharma services. It competes with EVERSANA's 3PL, specialty pharmacy, and patient access businesses, particularly in specialty and oncology distribution.
• Cencora (formerly AmerisourceBergen): Cencora is one of the largest pharmaceutical distribution and specialty services companies in the U.S., offering distribution, patient services, and consulting. It overlaps with EVERSANA's 3PL, specialty pharmacy, and patient services offerings for pharma manufacturers.

Direct peers

• Trinity Life Sciences: Trinity Life Sciences is a life sciences strategy and commercial analytics consultancy that recently acquired EVERSANA's APACME advisory business. It is a direct competitor in pharma advisory, market access strategy, and commercial insights.
• Syneos Health: Syneos Health (now privately held) is a direct competitor in biopharmaceutical commercialization services, offering contract sales, medical affairs, and patient engagement solutions. It is highly comparable to EVERSANA's field deployment, market access, and patient services offerings targeting similar pharma/biotech clients.
• ZS Associates: ZS Associates is a global management consulting and technology firm specializing in life sciences, offering sales/marketing effectiveness, AI-driven analytics, and patient engagement. It directly competes with EVERSANA's consulting, market access, and AI-driven commercialization solutions for pharma clients.

Emerging players

• Definitive Healthcare: Definitive Healthcare provides commercial intelligence and analytics for the healthcare and life sciences industries, similar to EVERSANA's NAVLIN pricing/access data and Commercial Intelligence 360. It is an emerging data-software player competing for the same market access and commercialization intelligence budgets.
• Veeva Systems: Veeva Systems provides cloud-based life sciences software (CRM, regulatory, clinical) used by pharma manufacturers globally. While Veeva is primarily software vs. EVERSANA's services, both compete to capture pharma commercialization and data workflow spend — including regulatory, medical affairs, and commercial data management.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/eversana
• Xx.com/eversanacompany

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles22 records

Subsidiaries6 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A13 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EVERSANA